Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer
Post-hoc analysis from Phase 3 SPOTLIGHT trial demonstrated consistent performance between African Americans and other patient groups for FDA-approved POSLUMA in men with recurrent prostate cancer

Read more on:
https://www.itnonline.com/content/blue-earth-diagnostics-bracco-company-announces-results-evaluating-diagnostic-performance